stocks

Technology company Kromek (LON: KMK) saw shares sink nearly 10 percent on Wednesday, after recording a £1.5 million loss for the year to April 2017.

The company, who focus on the medical, security screening and nuclear markets, saw revenue increase 7.5 percent to £9 million, with product sales accounting for 74 percent of total revenues.

The company still recorded a £1.5 million EBITDA loss for the year, an improvement on the £2.4 million loss seen last year, with loss before tax for the year was £3.8 million. This came despite attracting further investment of £3.5 million.

The company provides radiation detection products for the medical, security screening and nuclear markets, based on cadmium zinc telluride and other advanced technologies.

Shares in Kromek are currently trading down 9.13 percent at 32.83 (1058GMT).

Previous articleIMF lower growth US growth forecasts on Trump uncertainty
Next articleFCA cracks down on unclear pricing structures in investment sector
Miranda is the online editor of UK Investor Magazine. Her interests include private equity, crowdfunding, peer-to-peer lending, gender equality and coffee.